Anti-CD20 (Rituximab biosimilar - IgG4 isotype)

Product Unit size Cat. code Docs. Qty. Price


Human CD20 (rituximab) antibody - Human IgG4

Show product

100 µg

3 x 100 µg

  • About
  • Specifications
  • Contents

Monoclonal human IgG4 antibody against human CD20

Anti-hCD20-hIgG4 features the constant region of the human IgG4 isotype and the variable region of rituximab.

Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes.

Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity.

Rituximab has been approved by the FDA for the treatment of various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukaemia.

Anti-hCD20-hIgG4 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.


Back to the top


Clonality: Monoclonal antibody

Specificity: Targets cells expressing human CD20

Isotype: Human IgG4, kappa

Back to the top


Anti-hCD20-hIgG4 purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:

  • hcd20-mab4: 100 µg
  • hcd20-mab4-03: 3 x 100 µg

room temperature Product is shipped at room temperature.

store Upon receipt, store at -20°C.


Back to the top
Customer Service
& Technical Support
Shopping cart is empty